DNA methylation biomarkers of cancer: Moving toward clinical application

Pharmacogenomics

Volumn 5, Issue 6, 2004, Pages 699-707

  Levenson, Victor V ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Assay development; Biomarker; Cancer; Clinical application; DNA methylation; Methylation profile

Indexed keywords

BIOLOGICAL MARKER; DNA; GAMMA INTERFERON; RESTRICTION ENDONUCLEASE;

ARTICLE; BIOASSAY; CANCER DIAGNOSIS; CANCER RESEARCH; CHEMICAL MODIFICATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DNA DETERMINATION; DNA METHYLATION; DNA SEQUENCE; ENZYME DEGRADATION; HUMAN; INDIVIDUALIZATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; VALIDATION PROCESS;

DNA METHYLATION; HUMANS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 4544340792     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.5.6.699     Document Type: Article

References (62)

1. Barden CB, Shister KW, Zhu B et al.: Classification of follicular thyroid tumors by molecular signature: results of gene profiling. Clin. Cancer Res. 9, 1792-1800 (2003).
2. Srinivas PR, Verma M, Zhao Y, Srivastava S: Proteomics for cancer biomarker discovery. Clin. Chem. 48, 1160-1169 (2002).
3. Wang X, Nakamura M, Mori I et al.: Calcitonin receptor gene and breast cancer: quantitative analysis with laser capture microdissection. Breast Cancer Res. Treat. 83, 109-117 (2004).
4. Weigelt B, Verduijn P, Bosma AJ, Rutgers EJ, Peterse HL, van't Veer LJ: Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple mRNA markers. Br. J. Cancer 90, 1531-1537 (2004).
5. Moul JW, Merseburger AS, Srivastava S: Molecular markers in prostate cancer: the role in preoperative staging. Clin. Prostate Cancer 1, 42-50 (2002).
6. Wulfkuhle JD, Liotta LA, Petricoin EF: Proteomic applications for the early detection of cancer. Nat. Rev. Cancer 3, 267-275 (2003).
7. Bandera CA, Ye B, Mok SC: New technologies for the identification of markers for early detection of ovarian cancer. Curr. Opin. Obstet. Gynecol. 15, 51-55 (2003).
8. Crisan D, Mattson JC: Retrospective DNA analysis using fixed tissue specimens. DNA Cell Biol. 12, 455-464 (1993).
9. Lehmann U, Kreipe H: Real-time PCR analysis of DNA and RNA extracted from formialin-fixed and paraffin-embedded biopsies. Methods 25, 409-418 (2001).
10. Shi SR, Cote RJ, Wu L et al.: DNA extraction from archival formalin-fixed, paraffin-embedded tissue sections based on the antigen retrieval principle: heating under the influence of pH. J. Histochem. Cytochem. 50, 1005-1011 (2002).
11. Benchekroun M, Degraw J, Gao J et al.: Impact of fixative on recovery of mRNA from paraffin-embedded tissue. Diagn. Mol. Pathol. 13, 116-125 (2004).
12. Macabeo-Ong M, Ginzinger DG, Dekker N et al.: Effect of duration of fixation on quantitative reverse transcription polymerase chain reaction analyses. Mod. Pathol. 15, 979-987 (2002).
13. Abrahamsen HN, Steiniche T, Nexo E, Hamilton-Dutoit SJ, Sorensen BS: Towards quantitative mRNA analysis in paraffin-embedded tissues using real-time reverse transcriptase-polymerase chain reaction: a methodological study on lymph nodes from melanoma patients. J. Mol. Diagn. 5, 34-41 (2003).
14. Symmans WF, Ayers M, Clark EA et al.: Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer 97, 2960-2971 (2003).
15. Beck JS: Observer variability in reporting of breast lesions. J. Clin. Pathol. 38, 1358-1365 (1985).
16. Feinberg AP, Tycko B: The history of cancer epigenetics. Nat. Rev. Cancer 4, 143-153 (2004).
17. Laird PW: The power and the promise of DNA methylation markers. Nat. Rev. Cancer 3, 253-266 (2003).
18. Herman JG, Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349, 2042-2054 (2003).
19. Fraga MF, Esteller M: DNA methylation: a profile of methods and applications. Biotechniques 33(3), 632, 634, 636-649 (2002).
20. Urnov FD: Chromatin as a tool for the study of genome function in cancer. Ann. NY Acad. Sci. 983, 5-21 (2003).
21. Geiman TM, Robertson KD: Chromatin remodeling, histone modifications, and DNA methylation - how does it all fit together? J. Cell Biochem. 87, 117-125 (2002).
22. Jones PA: DNA methylation and cancer. Oncogene 21, 5358-5360 (2002).
23. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA 93, 9821-9826 (1996).
24. Liu ZJ, Maekawa M: Polymerase chain reaction-based methods of DNA methylation analysis. Anal. Biochem. 317, 259-265 (2003).
25. Patel A, Groopman JD, Umar A: DNA methylation as a cancer-specific biomarker: from molecules to populations. Ann. NY Acad. Sci. 983, 286-297 (2003).
26. Cottrell SE, Laird PW: Sensitive detection of DNA methylation. Ann. NY Acad. Sci. 983, 120-130 (2003).
27. Smiraglia DJ, Plass C: The development of CpG island methylation biomarkers using restriction landmark genomic scanning. Ann. NY Acad. Sci. 983, 110-119 (2003).
28. Shi H, Maier S, Nimmrich I et al.: Oligonucleotide-based microarray for DNA methylation analysis: principles and applications. J. Cell. Biochem. 88, 138-143 (2003).
29. Rush LJ, Plass C: Restriction landmark genomic scanning for DNA methylation in cancer: past, present, and future applications. Anal. Biochem. 307, 191-201 (2002).
30. Shiraishi M, Oates AJ, Sekiya T: An overview of the analysis of DNA methylation in mammalian genomes. Biol. Chem. 383, 893-906 (2002).
31. Wong IH, Lo YM, Johnson PJ: Epigenetic tumor markers in plasma and serum: biology and applications to molecular diagnosis and disease monitoring. Ann. NY Acad. Sci. 945, 36-50 (2001).
32. Herman JG, Baylin SB: Promoter-region hypermethylation and gene silencing in human cancer. Curr. Top. Microbiol. Immunol. 249, 35-54 (2000).
33. Thomassin H, Oakeley EJ, Grange T: Identification of 5-methylcytosine in complex genomes. Methods 19, 465-475 (1999).
34. Dahl C, Guldberg P: DNA methylation analysis techniques. Biogerontology 4, 233-250 (2003).
35. Frommer M, Mcdonald LE, Millar DS et al.: A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl. Acad. Sci. USA 89, 1827-1831 (1992).
36. Clark SJ, Harrison J, Paul CL, Frommer M: High sensitivity mapping of methylated cytosines. Nacleic Acids Res. 22, 2990-2997 (1994).
37. Sharp PA, Sugden B, Sambrook J: Detection of two restriction endonuclease activities in Haemophilus parainfluenzae using analytical agarose-ethidium bromide electrophoresis. Biochemistry 12, 3055-3063 (1973).
38. Senesac JH, Allen JR: Oligonucleotide activation of the type IIe restriction enzyme NaeI for digestion of refractory sites. Biotechniques 19, 990-993 (1995).
39. Topal MD, Thresher RJ, Conrad M, Griffith J: NaeI endonuclease binding to pBR322 DNA induces looping. Biochemistry 30, 2006-2010 (1991).
40. Mucke M, Lurz R, Mackeldanz P, Behlke J, Kruger DH, Reuter M: Imaging DNA loops induced by restriction endonuclease EcoRII. A single amino acid substitution uncouples target recognition from cooperative DNA interaction and cleavage. J. Biol. Chem. 275, 30631-30637 (2000).
41. Senesac JH, Romanin JK: Application of oligonucleotide activation to restriction endonuclease NarI. Biotechniques 22(6), 1166-1168 (1997).
42. Costello JF, Fruhwald MC, Smiraglia DJ et al.: Aberrant CpG-island methylation has non-random and tumor-type-specific patterns. Nat. Genet. 24, 132-138 (2000).
43. Huang TH, Perry MR, Laux DE: Methylation profiling of CpG islands in human breast cancer cells. Hum. Mol. Genet. 8, 459-470 (1999).
44. Singer-Sam J, Grant M, Lebon JM et al.: Use of a HpaII-polymerase chain reaction assay to study DNA methylation in the Pgk-1 CpG island of mouse embryos at the time of X chromosome inactivation. Mol. Cell. Biol. 10, 4987-4989 (1990).
45. Singer-Sam J, Lebon JM, Tanguay RL, Riggs AD: A quantitative HpaII-PCR assay to measure methylation of DNA from a small number of cells. Nucleic Acids Res. 18, 687 (1990).
46. Fackler MJ, Mcveigh M, Mehrotra J et al.: Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res. 64, 4442-4452 (2004).
47. Zemliakova VV, Zhevlova AI, Strel'nikov VV et al.: [Abnormal methylation of several tumor suppressor genes in sporadic breast cancer.] Mol. Biol. (Mosk.) 37, 696-703 (2003).
48. Dietz LG, Wylie AA, Rauen KA, Murphy SK, Jirtle RL, Cotter PD: Exclusion of maternal uniparental disomy of chromosome 14 in patients referred for Prader-Willi syndrome using a multiplex methylation polymerase chain reaction assay. J. Med. Genet. 40, e46 (2003).
49. Uhlmann K, Rohde K, Zeller C et al.: Distinct methylation profiles of glioma subtypes. Int. J. Cancer 106, 52-59 (2003).
50. Muller HM, Fiegl H, Widschwendter A, Widschwendter M: Prognostic DNA methylation marker in serum of cancer patients. Ann. NY Acad. Sci. 1022, 44-49 (2004).
51. Nam JM, Stoeva SI, Mirkin CA: Bio-barcode-based DNA detection with PCR-like sensitivity. J. Am. Chem. Soc. 126, 5932-5933 (2004).
52. Yano S, Ghosh P, Kusaba H, Buchholz M, Longo DL: Effect of promoter methylation on the regulation of IFN-γ gene during in vitro differentiation of human peripheral blood T cells into a Th2 population. J. Immunol. 171, 2510-2516 (2003).
53. INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res. 55, 6200-6209 (1995).
54. Brock GJ, Huang TH, Chen CM, Johnson KJ: A novel technique for the identification of CpG islands exhibiting altered methylation patterns (ICEAMP). Nucleic Acids Res. 29, E123 (2001).
55. Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J, Sukumar S: Hypermethylation of 14-3-3 σ (stratifin) is an early event in breast cancer. Oncogene 20, 3348-3353 (2001).
56. Esteller M, Corn PG, Baylin SB, Herman JG: A gene hypermethylation profile of human cancer. Cancer Res. 61, 3225-3229 (2001).
57. Garcia-Olmo DC, Ruiz-Piqueras R, Garcia-Olmo L: Circulating nucleic acids in plasma and serum (CNAPS) and its relation to stem cells and cancer metastasis: state of the issue. Histol. Histopathol. 19, 575-583 (2004).
58. INK4a sequences in plasma, serum, and blood cells of hepatocellular carcinoma patients. Clin. Cancer Res. 9, 1047-1052 (2003).
59. Ziegler A, Zangemeister-Wittke U, Stahel RA: Circulating DNA: a new diagnostic gold mine? Cancer Treat. Rev. 28, 255-271 (2002).
60. Adorjan P, Distler J, Lipscher E et al.: Tumor class prediction and discovery by microarray-based DNA methylation analysis. Nacleic Acids Res. 30, E21 (2002).
61. Siegmund KD, Laird PW, Laird-Offringa IA: A comparison of cluster analysis methods using PNA methylation data. Bioinformatics 20(12), 1896-1904 (2004).
62. Barker PE: Cancer biomarker validation: standards and process: roles for the National Institute of Standards and Technology (NIST). Ann. NY Acad. Sci. 983, 142-150 (2003).